N/A N=50 Efficacy and Feasibility of a Personalized Treatment for Depression With Co-Occurring Anxiety
Depression · Anxiety
Primary: Number of Participants Meeting Depression Remission Criteria — 10; 15 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=200 Depression and Anxiety in Rheumatoid Arthritis
Rheumatoid Arthritis · Depression · Anxiety
Primary: Hospital Anxiety and Depression Scale (HADS) — 107; 46; 20; 27 participants
N/A N=56 Anxiety in Older Veterans
Anxiety Disorders
Primary: Change in Anxiety Symptoms — 1.77; -2.42 units on a scale
Phase 4 N=69 Anxiety and Depression in Epilepsy: A Treatment Study
Anxiety · Depression · Epilepsy
Primary: Adherence to Intervention — 2; 0; 0 Participants
N/A N=151 Clinical Management of Anxiety and Access to Health Care
Dental Anxiety
Primary: Change in Modified Dental Anxiety Scale — 19.5; 19.6; 15.4; 17.6 units on a scale — p=<0.05
N/A N=116 Mindfulness, Group Therapy and Psychosis; Training Decreases Anxiety and Depression
Psychosis
Primary: Change in Generalized Anxiety Disorder-7 Pre/Post Test at Week 5 — 4.68; 6.28; 3.96; 7.38 units on a scale — p=0.003
N/A N=30 EMR Outcomes: Anxiety and Depression in Epilepsy
Quality of Life · Anxiety · Depression
Primary: Percentage of Participants Retained in the Study in the EMR Arm — 67 percentage of participants
N/A N=63 Digital Intervention to Treat Anxiety and Depression Among Persons Receiving Treatment for Opioid Use Disorder
Opioid-use Disorder · Anxiety Disorders · Depressive Disorder
Primary: Change in Anxiety Symptoms as Assessed by Generalized Anxiety Disorder- Q-IV Scale — -1.8; -1.04; -2.47; -1.53 units on a scale — p=.755
N/A N=1,206 Epidemiology of Depression, Anxiety, and Cognitive Impairment
Depression · Anxiety · Cognitive Impairment
Primary: Participants With Depression by Patient Health Questionnaire - 9 — 177 participants
Phase 4 N=89 Stress Reduction Techniques and Anxiety: Therapeutic and Neuroendocrine Effects
Generalized Anxiety Disorder
Primary: Active Symptoms of Generalized Anxiety Disorder — 13.65; 16.27 units on a scale
N/A N=128 Exercise and Pharmacotherapy for Anxiety in Cardiac Patients
Anxiety · Cardiovascular Disease
Primary: Change in Hospital Anxiety and Depression Scale (HADS), Anxiety — -3.9; -5.7; -3.5 score on a scale — p=0.038
N/A N=37 A Unified Treatment for Anxiety Disorders
Emotional Disorders · Anxiety Disorders
Primary: Anxiety Disorders Interview Schedule for DSM-IV — 5.23; 5.09; 3.18; 5.14 score on a scale
N/A N=167 Psychotherapy for Anxiety in Children With Autism Spectrum Disorder
Autism Spectrum Disorders · Autism · Asperger's Syndrome
Primary: Change From Baseline in Anxiety Severity on the Pediatric Anxiety Rating Scale After 16 Weeks of Treatment. — 3.43; 3.47; 3.28; 2.13 units on a scale
N/A N=35 Reducing Anxiety and Stress in Primary Care Patients
Anxiety
Primary: Generalized Anxiety Disorder-7 at Post-Assessment — 12.5; 12.0; 4.6; 9.1 score on a scale — p=0.035
Phase 4 N=40 Depression, Epinephrine, and Platelet Function
Major Depressive Disorder
Primary: Response of Participants, Defined by Change in the 21-item Hamilton Depression Rating Scale (HDRS) From Baseline to Week8 — 5; 9; 2; 4 participants — p=.918
N/A N=880 Tools for Anxiety and Depression Screening in Epilepsy
Epilepsy
Primary: Percentage of Subjects Completing Screening Instruments — 0; 14; 19; 12 Percentage who completed
Phase 4 N=183 A Collaborative Care Program to Improve Treatment of Depression and Anxiety Disorders in Cardiac Patients
Depression · Generalized Anxiety Disorder · Panic Disorder
Primary: Change in Mental Health-related Quality of Life From Baseline to 24 Weeks — 8.87; 8.39 units on a scale — p=0.002
Phase 3 N=81 Psychosocial and Medication Treatment for Anxiety in Alcoholism
Alcohol-Related Disorders · Anxiety Disorders
Primary: Clinical Global Impression Scale-I (CGI-I) — 3.65; 3.81; 3.86; 4.05 units on a scale
N/A N=29 Positive Valence System Enhancement Treatment for Anxiety and Depression: Clinical Efficacy and Neural Changes
Anxiety Disorders and Symptoms · Depression
Primary: Change From Baseline in Positive Affect (Positive and Negative Affect Schedule; Modified Differential Emotions Scale; Composite) — -0.41; -0.40; 0.73; -0.02 z-score
N/A N=75 Assessing Mechanisms of Anxiety Reduction in Animal-assisted Interventions
Social Anxiety Disorder · Social Anxiety · Social Anxiety Disorder of Childhood
Primary: Self-reported Affective Experience — 10.19; 10.00; 10.28; 8.33 units on a scale — p=.723
Phase 4 N=32 Drug Treatment Validation of Functional Magnetic Resonance Imaging in Generalized Anxiety Disorder
Generalized Anxiety Disorder
Primary: Signal Change in Brain Activity in the Amygdala When Viewing Emotional Faces — .1489; .1074; .0119; .1404 Percent signal change in brain acitivity
N/A N=18 Novel Anxiety Treatment
Cognitive Training · Anxiety Disorders
Primary: Change in Symptoms of Anxiety Based on Screen for Anxiety and Related Disorders (SCARED) Parent Report at Baseline and Post Assessment — -20.4; -21.12 units on a scale
Phase 3 N=265 Transdiagnostic Cognitive Behavioral Treatment for Anxiety
Anxiety Disorders
Primary: CRIS-EPS: Comparison of Extent of Participation Scores Among iCBT, sCBT, and TAU Groups From Baseline to 1, 3, and 6 Month Follow Ups — 4.21; 4.18; 4.17; 4.52 score on a…
N/A N=12 Video-visit Behavior Therapy for Anxiety and Depression in Youth
Anxiety · Depression
Primary: Minimum Attendance — 5; 7 Participants
N/A N=94 Approach-Avoidance Conflict-a Multi-level Predictor for Therapy Response
Generalized Anxiety Disorder
Primary: For Aim1: Baseline Generalized Anxiety Disorder Symptoms as Measured by the Generalized Anxiety Disorder - 7 Item Scale (GAD-7). — 12.85; 11.62 units on a scale — p=.088
N/A N=27 Strategies for Treating Anxiety Research Study
Anxiety Disorders · Anxiety
Primary: Number of Patient Participants Retained in the Intervention (Out of All of Those Enrolled), as Measured by Completion to All Study Treatment Visits. — 17 Participants
Phase 2 N=33 Cognitive Behavioral Therapy (CBT) for Anxiety Disorders in Autism: Adapting Treatment for Adolescents
Anxiety Disorders in Youth With Autism, Asperger's Syndrome, and Pervasive Developmental Disorder Not Otherwise Specified
Primary: Pediatric Anxiety Rating Scale. — 11.62; 14.04 units on a scale — p=.04
N/A N=15 Assessing Visual Processing in High Anxiety
Anxiety
Primary: Tolerability of the Micro Expression Training Task in Individuals With High Anxiety — 5; 6 Participants
Phase 2 N=24 Treatment of Anxiety and Anorexia Nervosa in Adolescents
Anxiety · Anorexia Nervosa
Primary: Medication Side Effects Score — 9.5; 6.2; 6.4; 4.1 Score on a scale
N/A N=256 Meditation and Kundalini Yoga for Heightened Anxiety Related to COVID-19
Generalized Anxiety · Health Anxiety
Primary: GAD-7 — 4.7; 7.8; 4.9 score on a scale — p=0.071